- Published on
KembaraXtra- Medicine- Arrhythmogenic Right Ventricular Dysplasia
Arrhythmogenic right ventricular dysplasia (ARVD), also known as arrhythmogenic right ventricular cardiomyopathy (ARVC), is a cardiomyopathy characterized by progressive replacement of normal myocardium with fibrous or fibrofatty tissue, predominantly affecting the right ventricle and occasionally the lateral or posterior left ventricle. Classically, pathologic changes were described in the “triangle of dysplasia,” involving the right ventricular inflow tract, outflow tract, and apex, although early disease may spare the apex. Clinically, ARVD presents with palpitations, syncope, potentially life-threatening right-sided ventricular arrhythmias, and in later stages, right or biventricular heart failure.
The estimated prevalence of ARVD in adults ranges from 1 in 2,000 to 1 in 5,000, and it is a leading cause of arrhythmic cardiac arrest in young individuals and athletes. The mean age at presentation is 31 years (range 12–50 years), with a male predominance. A family history is present in nearly 50% of affected patients. The disease is most commonly inherited in an autosomal dominant pattern with variable penetrance and phenotypic expression, although rare autosomal recessive forms exist (e.g., Naxos disease). Mutations in desmosomal proteins are central to pathogenesis, and identifiable gene mutations are found in approximately 50% of patients.
Clinically, ARVD shows marked heterogeneity. Patients may remain asymptomatic for years or present with palpitations, syncope, chest discomfort, ventricular tachycardia, sudden cardiac arrest, or signs of right ventricular failure such as dyspnea, edema, and fatigue. Cardiac arrest may be the initial manifestation, occurring either with exertion or at rest. Physical examination is often normal, but a widely split second heart sound (S2) may provide an important diagnostic clue.
Pathophysiologically, ARVD results from apoptotic myocardial cell death due to desmosomal protein mutations, followed by replacement with fatty or fibrofatty tissue and scattered residual myocytes. Disease progression leads to electrical instability and ventricular arrhythmias. Although classically right-sided, involvement of the posterolateral left ventricle may occur, typically sparing the interventricular septum.
Diagnosis is based on a point-based Task Force system, in which major criteria score 2 points and minor criteria 1 point. A total of 4 points confirms a definite diagnosis, while 3 points indicates probable ARVD. Criteria incorporate structural abnormalities, tissue characterization, repolarization and depolarization abnormalities, arrhythmias, and family history or genetic findings.
The differential diagnosis includes other cardiomyopathies with right ventricular involvement, idiopathic right ventricular tachycardia, sarcoidosis, right ventricular infarction, and Uhl anomaly, a rare childhood disorder characterized by a “paper-thin” right ventricle.
Evaluation begins with a detailed history emphasizing sudden cardiac death in relatives, followed by resting ECG, 24-hour Holter monitoring, signal-averaged ECG, and cardiac imaging. ECG abnormalities are present in 50%–90% of patients and may include T-wave inversions in V1–V6, epsilon waves, and QRS prolongation in right precordial leads. Holter monitoring may reveal frequent premature ventricular contractions (>500/24 h) or ventricular tachycardia with a left bundle branch block morphology. Echocardiography often shows right ventricular dilation, regional wall motion abnormalities, aneurysms, and depressed RV function. Cardiac MRI is the most sensitive noninvasive modality for detecting fibrofatty infiltration and regional dysfunction, though false-positive rates are high. Cardiac CT may demonstrate RV wall thinning and aneurysmal dilation. Endomyocardial biopsy and electrophysiologic testing are reserved for inconclusive cases and are rarely performed routinely.
There is no curative therapy for ARVD. Management focuses on prevention of sudden cardiac death, control of ventricular arrhythmias, and treatment of heart failure. Cardioselective beta-blockers (e.g., metoprolol succinate) are recommended both for patients with prior ventricular arrhythmias and for prophylaxis. Antiarrhythmic therapy, typically sotalol as first line or amiodarone, often combined with beta-blockers, is used to suppress ventricular tachycardia.
Nonpharmacologic strategies are critical. Avoidance of moderate to high-intensity exercise is strongly recommended, as physical activity can trigger arrhythmias and accelerate disease progression. Implantable cardioverter-defibrillator (ICD) placement should be considered in patients who are survivors of sudden cardiac arrest, have sustained or symptomatic ventricular tachycardia or fibrillation, documented asymptomatic ventricular arrhythmias, or a left ventricular ejection fraction ≤35%. High-risk features include unexplained syncope, advanced disease, significant ventricular arrhythmias, and a family history of sudden cardiac death. Subcutaneous ICDs may be an alternative to transvenous systems. Radiofrequency catheter ablation is reserved for refractory ventricular tachycardia, and cardiac transplantation is an option for end-stage disease.
Early referral to cardiology and electrophysiology is essential, and genetic counseling should be considered. All first-degree relatives of confirmed cases should undergo screening. Sports participation significantly increases the risk of sudden cardiac death in adolescents and young adults with ARVD. Estimated overall mortality ranges from 0.08% to 3.6% per year, underscoring the importance of early diagnosis, lifestyle modification, and appropriate risk-stratified therapy.
Arrhythmogenic right ventricular dysplasia (ARVD), also known as arrhythmogenic right ventricular cardiomyopathy (ARVC), is a cardiomyopathy characterized by progressive replacement of normal myocardium with fibrous or fibrofatty tissue, predominantly affecting the right ventricle and occasionally the lateral or posterior left ventricle. Classically, pathologic changes were described in the “triangle of dysplasia,” involving the right ventricular inflow tract, outflow tract, and apex, although early disease may spare the apex. Clinically, ARVD presents with palpitations, syncope, potentially life-threatening right-sided ventricular arrhythmias, and in later stages, right or biventricular heart failure.
The estimated prevalence of ARVD in adults ranges from 1 in 2,000 to 1 in 5,000, and it is a leading cause of arrhythmic cardiac arrest in young individuals and athletes. The mean age at presentation is 31 years (range 12–50 years), with a male predominance. A family history is present in nearly 50% of affected patients. The disease is most commonly inherited in an autosomal dominant pattern with variable penetrance and phenotypic expression, although rare autosomal recessive forms exist (e.g., Naxos disease). Mutations in desmosomal proteins are central to pathogenesis, and identifiable gene mutations are found in approximately 50% of patients.
Clinically, ARVD shows marked heterogeneity. Patients may remain asymptomatic for years or present with palpitations, syncope, chest discomfort, ventricular tachycardia, sudden cardiac arrest, or signs of right ventricular failure such as dyspnea, edema, and fatigue. Cardiac arrest may be the initial manifestation, occurring either with exertion or at rest. Physical examination is often normal, but a widely split second heart sound (S2) may provide an important diagnostic clue.
Pathophysiologically, ARVD results from apoptotic myocardial cell death due to desmosomal protein mutations, followed by replacement with fatty or fibrofatty tissue and scattered residual myocytes. Disease progression leads to electrical instability and ventricular arrhythmias. Although classically right-sided, involvement of the posterolateral left ventricle may occur, typically sparing the interventricular septum.
Diagnosis is based on a point-based Task Force system, in which major criteria score 2 points and minor criteria 1 point. A total of 4 points confirms a definite diagnosis, while 3 points indicates probable ARVD. Criteria incorporate structural abnormalities, tissue characterization, repolarization and depolarization abnormalities, arrhythmias, and family history or genetic findings.
The differential diagnosis includes other cardiomyopathies with right ventricular involvement, idiopathic right ventricular tachycardia, sarcoidosis, right ventricular infarction, and Uhl anomaly, a rare childhood disorder characterized by a “paper-thin” right ventricle.
Evaluation begins with a detailed history emphasizing sudden cardiac death in relatives, followed by resting ECG, 24-hour Holter monitoring, signal-averaged ECG, and cardiac imaging. ECG abnormalities are present in 50%–90% of patients and may include T-wave inversions in V1–V6, epsilon waves, and QRS prolongation in right precordial leads. Holter monitoring may reveal frequent premature ventricular contractions (>500/24 h) or ventricular tachycardia with a left bundle branch block morphology. Echocardiography often shows right ventricular dilation, regional wall motion abnormalities, aneurysms, and depressed RV function. Cardiac MRI is the most sensitive noninvasive modality for detecting fibrofatty infiltration and regional dysfunction, though false-positive rates are high. Cardiac CT may demonstrate RV wall thinning and aneurysmal dilation. Endomyocardial biopsy and electrophysiologic testing are reserved for inconclusive cases and are rarely performed routinely.
There is no curative therapy for ARVD. Management focuses on prevention of sudden cardiac death, control of ventricular arrhythmias, and treatment of heart failure. Cardioselective beta-blockers (e.g., metoprolol succinate) are recommended both for patients with prior ventricular arrhythmias and for prophylaxis. Antiarrhythmic therapy, typically sotalol as first line or amiodarone, often combined with beta-blockers, is used to suppress ventricular tachycardia.
Nonpharmacologic strategies are critical. Avoidance of moderate to high-intensity exercise is strongly recommended, as physical activity can trigger arrhythmias and accelerate disease progression. Implantable cardioverter-defibrillator (ICD) placement should be considered in patients who are survivors of sudden cardiac arrest, have sustained or symptomatic ventricular tachycardia or fibrillation, documented asymptomatic ventricular arrhythmias, or a left ventricular ejection fraction ≤35%. High-risk features include unexplained syncope, advanced disease, significant ventricular arrhythmias, and a family history of sudden cardiac death. Subcutaneous ICDs may be an alternative to transvenous systems. Radiofrequency catheter ablation is reserved for refractory ventricular tachycardia, and cardiac transplantation is an option for end-stage disease.
Early referral to cardiology and electrophysiology is essential, and genetic counseling should be considered. All first-degree relatives of confirmed cases should undergo screening. Sports participation significantly increases the risk of sudden cardiac death in adolescents and young adults with ARVD. Estimated overall mortality ranges from 0.08% to 3.6% per year, underscoring the importance of early diagnosis, lifestyle modification, and appropriate risk-stratified therapy.
0 Comments
